Uric acid levels in tuberculosis patients receiving pyrazinamide-ethambutol
Keywords:
ethambutol, hyperuricemia, tuberculosis, pyrazinamide, uric acidAbstract
Pyrazinamide and ethambutol are essential components of anti-tuberculosis therapy; however, both drugs can affect uric acid metabolism and increase the risk of hyperuricemia. Elevated uric acid levels may potentially cause joint pain and other metabolic disorders that can affect patient adherence to therapy. This study aims to analyze changes in serum uric acid levels before and after the administration of pyrazinamide–ethambutol combination therapy in tuberculosis patients. The study employed a retrospective analytical observational design using secondary data from the medical records of tuberculosis patients undergoing treatment at three type D regional general hospitals in West Jakarta. A sample of 100 patients was selected using a total sampling method. Data analysis was performed using descriptive statistics and a paired-samples t-test. The results showed an increase in the mean serum uric acid levels in both male and female patients after four weeks of therapy. Male patients had higher uric acid levels than females, although the increase was significant in both groups. These findings suggest that pyrazinamide–ethambutol combination therapy leads to an increase in serum uric acid levels during the intensive phase of tuberculosis treatment. Therefore, regular monitoring of uric acid levels is essential for early detection of hyperuricemia and for optimizing patient management in tuberculosis.
Downloads
References
Abdullaey, R. Y., Komissarova, O. G., Chumakoya, E. S., & Odinets, V. S. (2017). Level of uric acid in blood serum of new pulmonary tuberculosis patients with multiple drug resistance. Tuberculosis and Lung Diseases, 95(4), 31–36. doi: 10.21292/2075-1230-2017-95-4-31-36
Adha, A. W., Keswara, U. R., & Winarno, R. (2024). Faktor pejamu (host) yang berhubungan dengan kejadian tuberkulosis paru. Manuju: Malahayati Nursing Journal, 6(5), 1885–1893. https://doi.org/10.33024/mnj.v6i5.11360
Azzahra, I. P., Winarsih, S., & Yunita, E. P. (2023). Pengaruh obat antituberkulosis kombinasi RHZE terhadap peningkatan kadar asam urat. Media Pharmaceutica Indonesia, 5(2), 134–140. doi: 10.24123/mpi.v5i2.5925
Dewi, T. L., Saraswati, D., & Maywati, S. (2024). Faktor risiko yang berhubungan dengan kejadian tuberkulosis paru di wilayah kerja UPTD Puskesmas Purbaratu Kota Tasikmalaya tahun 2023. Jurnal Kesehatan Komunitas Indonesia, 20(1), 9–19. doi: 10.37058/jkki.v20i1.10552
Elsa, A., Antoro, B., & Sari, N. N. (2025). Faktor-faktor yang berhubungan dengan kejadian peningkatan kadar gula darah pada pasien TBC (tuberkulosis). Journal of Qualitative Health Research & Case Studies Reports, 5(4), 564–572. doi: 10.56922/quilt.v5i4.1512
Fortuna, T. A., Rachmawati, H., Hasmono, D., & Karuniawati, H. (2022). Studi penggunaan obat anti tuberkulosis (OAT) tahap lanjutan pada pasien baru BTA positif. Jurnal Farmasi Indonesia, 19(1), 62–71. doi: 10.23917/pharmacon.v19i1.17907
Hong, L., Liang, H., Man, W., Zhao, Y., & Guo, P. (2025). Estrogen and bacterial infection. Frontiers in Immunology, 1–14. doi: 10.3389/fimmu.2025.1556683
Indrasari, A. D., & Fathana, P. B. (2024). Studi literatur: Patogenesis dan diagnosis tuberkulosis resisten obat. Jurnal Medika Malahayati, 8(1), 162–169. doi: 10.33024/jmm.v8i1.13377
Jiangli, P., Jie, C., Yonggang, C., Lu, W., Na, L., Ji, L., Yi, H., Mingli, Y., & Jiangchun, Z. (2023). SLC22A12 gene polymorphism study on susceptibility to hyperuricemia induced by pyrazinamide. Chinese Journal of Anti-Tuberculosis, 45(2), 151–158. doi: 10.19982/j.issn.1000-6621.20220315
Louthrenoo, W., Hongsongkiat, S., Kasitanon, N., Wangkaew, S., & Jatuworapruk, K. (2015). Effect of antituberculous drugs on serum uric acid and urine uric acid excretion. Journal of Clinical Rheumatology, 21(7), 346–348. doi: 10.1097/RHU.0000000000000297
Mustaming, Farpina, E., Hartini, S., Pramono, J. S., & Toaha, A. (2022). Efek obat antituberkulosis fase intensif dan mengkonsumsi makanan yang mengandung purin terhadap kadar asam urat pasien tuberkulosis. The Journal of Muhammadiyah Medical Laboratory Technologist, 1(5). doi: 10.30651/jmlt.v5i1.7939
Nabilla, S., Setiadi, D. K., Astuti, A. P. K., & Ningrum, D. (2024). Gambaran tingkat stres pada penderita TB paru di wilayah kerja Puskesmas Cimalaka. Healthy Tadulako Journal, 10(1), 7–15. doi: 10.22487/htj.v10i1.952
Pitono, A. J., Ulfah, U., & Dini, N. (2021). Gambaran kadar asam urat pada penderita tuberkulosis paru yang mengkonsumsi obat anti tuberkulosis (OAT). Jurnal Kesehatan Rajawali, 11(2), 40–45. doi: 10.54350/jkr.v11i2.108
Putra, O. N., Purnamasari, T., & Hamami, N. M. (2024). Pyrazinamide-induced hyperuricemia in pulmonary tuberculosis patients. International Journal of Mycobacteriology, 13(3), 282–287. doi: 10.4103/ijmy.ijmy_178_23
Qureshi, W., Hassan, G., Kadri, S. M., Khan, G. Q., Samuel, B., & Arshad, A. (2007). Hyperuricemia and arthralgias during pyrazinamide therapy in patients with pulmonary tuberculosis. Laboratory Medicine, 38(8), 495–497. doi: 10.1309/7GBYQTY62PFEHDP1
Sasongko, D., & Hasan, H. (2020). Factors affecting uric acid changes in pulmonary tuberculosis patients who received oral anti tuberculosis therapy during one month. Medico-Legal Update, 20(2), 836–842. doi: 10.37506/mlu.v20i2.1220
Sazkiah, E. R., Alfiera, B., & Hardja, R. (2017). Distribusi penyakit tuberkulosis di Rumah Sakit Sri Pamela, 34(11), 1-1. doi: 10.22146/bkm.39866
Shin, H.-J., Yoon, J.-Y., Na, Y.-O., Lee, J.-K., Kho, B. G., Kim, T.-O., Kim, Y.-I., Lim, S.-C., Jeong, S.-H., & Kwon, Y.-S. (2023). Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment. PLoS ONE, 18(11). doi: 10.1371/journal.pone.0294490
Shinta, D. Y., Juliandi, M. D., Suryani, M. S., Sudji, I. R., Thressia, M., & Ms, H. S. (2025). Studi kesehatan lingkungan terhadap penderita tuberkulosis paru yang mengkonsumsi obat anti tuberkulosis (OAT). SEHATI, 5(2), 205–211. doi: 10.52364/sehati.v5i2.121
Solangi, G. A., Zuberi, B. F., Shaikh, S., & Shaikh, W. M. (2004). Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy. Journal of the College of Physicians and Surgeons Pakistan, 14(3), 136–138. https://pubmed.ncbi.nlm.nih.gov/15228843
Susilawati, N. M., Yudhaswara, N. A., & Octrisdey, K. (2023). Pengaruh lamanya pengobatan terhadap profil darah pada penderita tuberkulosis paru di Puskesmas Oesapa. Jurnal Ventilator, 1(4), 205-216. doi: 10.59680/ventilator.v1i4.706
Taki, H., Ogawa, K., Murakami, T., & Nikai, T. (2008). Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide. Kekkaku, 83(7), 497–501. https://pubmed.ncbi.nlm.nih.gov/18709966
Wibowo, Mulia, Y. S., Sunarno, Su’udi, A., Putranto, R. H., Kusumawati, K., & Renitia, G. I. (2023). Analisis kadar ureum, creatinin, dan asam urat pada OAT TB-paru. Jurnal Riset Kesehatan Poltekkes Depkes Bandung, 15(2), 442–449. doi: 10.34011/juriskesbdg.v15i2.2222
Widada, N. S., & Wulandari, A. (2021). Gambaran kadar asam urat pada pasien tuberkulosis paru sensitif obat setelah pengobatan fase intensif di Puskesmas Kecamatan Kramat Jati. Jurnal Analis Laboratorium Medik, 6(2), 85–92. doi: 10.51544/jalm.v6i2.2392
Wowiling, S., Djalil, R. H., & Suranata, F. M. (2021). Pengaruh edukasi tentang penyakit TB paru terhadap sikap penerimaan anggota keluarga yang menderita TB paru di Poliklinik TB DOTS (Directly Observed Treatment Short-Course) RSU GMIM Pancaran Kasih Manado. Jurnal Kesehatan Amanah, 5(1), 78–102. doi: 10.57214/jka.v5i1.201
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Angki Purwanti, Aryadnyani Ni Putu, Tri Prasetyorini (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Manuscript Template 
